Venetoclax,Ibrutinib
Roche,Abbvie,Janssen,Pharmacyclics
['cll', 'venetoclax', 'ncri,flair', ' ibru', 'flair study', 'lymsm']
congress | #ash22 munir, presents an updated interim analysis of the phase iii flair study. ibrutinib + venetoclax was shown to induce high rates of mrd-negativity in both ighv mutated and unmutated #cll
#lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm